Twenty dollars now, or fifty in two months. The question is older than any pharmacy, older than the stock exchange, older perhaps than money itself: the small bird in the hand against the larger one still in the bush. This autumn, inside the MindCORE research lab at the University of Pennsylvania, volunteers will answer it while lying in the tube of a magnetic resonance scanner, pressing a button as a machine watches the blood move through their brains. Some of them will have GLP-1 drugs — the weight-loss injections that have swept America — running in their veins. The scientists want to know whether the chemistry that silences the appetite for food also silences the appetite for risk.
The study is the first of its kind, and it comes from the Wharton School, where minds are trained to think about money. As CBS News reported, a growing body of research already suggests the drugs curb addictive behaviors beyond eating. Now Michael Platt, a neuroscientist and Wharton professor, and his colleagues intend to test what the drugs do to the body’s reward system — the network of brain structures, working with neurotransmitters such as dopamine, that reinforces certain behaviors and, in Platt’s description, underlies all consumption decisions.
We believe GLP-1s will ultimately lead to some structural remodeling of the brain, which is where some of those long-term impacts on food choice could show up, but also on financial decision-making.
That is Platt’s hypothesis, stated plainly to CBS News, and he goes further: “It might be very good financially for the average person — maybe they’re putting more money into savings.”
From the refrigerator to the trading floor
The idea did not begin in the laboratory. It began, as such ideas often do, with talk. The study is funded by Noom, a digital health company whose CEO, Geoff Cook, produced the earlier research from which the hypothesis stems. In an overview of the project, Platt offered a careful sentence: “There is anecdotal speculation in high-risk professions that dampening reward drive might also dampen appetite for risk and very high returns.” Stock traders, he means — men paid to feel the pulse of reward. “At the other end of the spectrum, the same shift could potentially help ordinary consumers resist impulsive spending and favor longer-term financial goals.”
Consider what the ordinary consumer is up against. A 2026 Northwestern Mutual study found that 73% of Americans had actively participated in, or considered pursuing, highly speculative activities — sports betting, cryptocurrencies — because they believed these methods more effective at reaching their financial goals than conventional, less risky ones such as index funds. Three citizens in four, in other words, looking at the slow road and choosing the casino door. Against that tide, Wharton proposes an injection: what discipline might otherwise take years to cultivate, delivered perhaps by syringe. One need not celebrate this to recognize the century in it.
Fourteen pictures and a button
The experiment itself is modest and methodical. Roughly 180 participants will pass through MindCORE between mid-October and about March 2027. They will answer questions about their demographic background, mental health and GLP-1 use, complete a short cognitive exercise, and then undergo MRI while performing four tasks — two on food, two on money — while scientists watch how their reward systems, which process value, reward and decision-making, respond.
The first financial task requires nothing but looking. Fourteen images will pass before the participants’ eyes: products, services, experiences, spending opportunities such as the Powerball jackpot. The technique is called passive viewing, and it records spontaneous responses without demanding any action. No recognizable brands or logos will appear, so that no neural signal is skewed by familiarity or preference. “The passive financial task allows us to compare responses to practical, need-based purchases versus more discretionary and enjoyment-oriented rewards,” the researchers wrote.
The second task demands a choice. Twenty dollars now, or fifty in two months, registered by a button on the machine. “It’s a trade-off between immediate gratification and getting something that you might know is actually of higher value, but you’d have to wait for it,” Platt said. The scanner records what the blood and oxygen say about how each option is valued. “One of our main questions concerns subjective value,” other researchers on the team told CBS News by email, “meaning how desirable a food or financial option is to a particular person, and whether this valuation differs with GLP-1 use.”
And here the design carries a small, honest cruelty. When the scan ends, each participant must follow through on one of the decisions made inside it. Whoever chose the fifty will wait the two months and be paid then. “That ensures that you are being honest and blind with your preferences,” Platt said. “You will have to face the consequences of your decision.”
What the syringe cannot answer
It is worth pausing on what is at stake here, because it is more than savings rates. A civilization that has built its marketplaces, its betting apps and its lotteries to exploit the reward system is now testing whether a molecule can defend the individual against the marketplace. If Platt is right, GLP-1s could help Americans resist risky financial decisions and develop better spending and saving habits; if he is wrong, the reward system will go on being mined as it always has been — by those who understand it far better than the people whose brains it governs. The drug, after all, has been studied as a brake on other appetites too. Power has always preferred its subjects temperate at their own expense and reckless at the house’s.
Either way, the fact that the question can be asked at all — that a professor at a business school can raise money to find out whether an injection will make a man prefer fifty dollars later to twenty now — tells you something about the hour. The will, that old faculty the philosophers argued over, is being photographed mid-decision in a basement lab in Philadelphia, one button press at a time.